Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

Université de Montréal

$105,000.00

Targeting M3R's internalization to treat Asthma and Chronic Obstructive Pulmonary Disease

FY 2018-19

Summary
Asthma and Chronic Obstructive Pulmonary Disease (COPD) are obstructive lung disorders affecting about 435 million individuals worldwide in which the symptoms of difficulty of breathing derived from the obstruction of the airways. In both respiratory disorders, this obstruction of the airways involves the activation of the muscarinic receptor M3 (M3R) leading to the contraction of the airway smooth muscle that compress the airways. Nevertheless, the current drugs blocking the M3R upregulate, paradoxically, their expression over time leading to negative side effects, such as an aggravation of airway hyperresponsiveness, a characteristic feature of asthma correlating with the symptoms. This project evaluates a new avenue to target M3R which avoids these side effects by inducing the receptor downregulation. M3R is a member of the large family of transmembrane proteins called G-protein coupled receptors (GPCRs). In a situation of over-activation, GPCRs downregulate their activity, a phenomenon called desensitization. Previously, we demonstrated, in vivo, that desensitization of the M3R has potential clinical benefits such as reversing the airway hyperresponsiveness in a murine model of asthma. This project aims to develop a compound that inducing exclusively the molecular pathways leading to the M3R's desensitization to treat asthma and COPD. For this purpose, firstly, the molecular pathways of contraction and desensitization will be characterized in tissue and cell-based models with molecular biology methods. Secondly, the actual compounds known to interact with the M3R will be screens to find some with a capacity to induce the desensitization of the receptor. Thirdly, these compounds will be chemically optimized, and their potential clinical benefits will be confirmed in murine models of asthma.
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
404183
Name
Mailhot-Larouche Samuel
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Targeting M3R's internalization to treat Asthma and Chronic Obstructive Pulmonary Disease
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Airway Responsiveness; Bronchodilatator; G Protein-Coupled Receptor; Muscarinic Receptor; Respiratory Physiology
Abstract
Asthma and Chronic Obstructive Pulmonary Disease (COPD) are obstructive lung disorders affecting about 435 million individuals worldwide in which the symptoms of difficulty of breathing derived from the obstruction of the airways. In both respiratory disorders, this obstruction of the airways involves the activation of the muscarinic receptor M3 (M3R) leading to the contraction of the airway smooth muscle that compress the airways. Nevertheless, the current drugs blocking the M3R upregulate, paradoxically, their expression over time leading to negative side effects, such as an aggravation of airway hyperresponsiveness, a characteristic feature of asthma correlating with the symptoms. This project evaluates a new avenue to target M3R which avoids these side effects by inducing the receptor downregulation. M3R is a member of the large family of transmembrane proteins called G-protein coupled receptors (GPCRs). In a situation of over-activation, GPCRs downregulate their activity, a phenomenon called desensitization. Previously, we demonstrated, in vivo, that desensitization of the M3R has potential clinical benefits such as reversing the airway hyperresponsiveness in a murine model of asthma. This project aims to develop a compound that inducing exclusively the molecular pathways leading to the M3R's desensitization to treat asthma and COPD. For this purpose, firstly, the molecular pathways of contraction and desensitization will be characterized in tissue and cell-based models with molecular biology methods. Secondly, the actual compounds known to interact with the M3R will be screens to find some with a capacity to induce the desensitization of the receptor. Thirdly, these compounds will be chemically optimized, and their potential clinical benefits will be confirmed in murine models of asthma.
Competitiondate
201810
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Mailhot-Larouche, Samuel
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~